Trial · NCT04109924
Adverse events80
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 80
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 14 | 42 | 14 |
| other | Blood and lymphatic system disorders - Other, specify | Blood and lymphatic system disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Watering eyes | Eye disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 5 | 42 | 5 |
| other | Anal pain | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Colitis | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Constipation | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 7 | 42 | 7 |
| other | Dental caries | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 30 | 42 | 30 |
| other | Dry mouth | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Dyspepsia | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Dysphagia | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Gastrointestinal disorders - Other, specify | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Mucositis oral | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 3 | 42 | 3 |
| other | Nausea | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 28 | 42 | 28 |
| other | Proctitis | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 2 | 42 | 2 |
| other | Rectal hemorrhage | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Stomach pain | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 1 | 42 | 1 |
| other | Vomiting | Gastrointestinal disorders | Treatment (Irinotecan, Bevacizumab, TAS-102) | 14 | 42 | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04109924/events